Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 15Terminated 2Recruiting 2Active not recruiting 2Withdrawn 1Unknown 1Suspended 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 501Breast 42Gastrointestinal 33Gynecologic 28Thoracic 24Head & Neck 13Dermatologic 13Sarcoma 7Lymphoid 7Plasma cell 5Other hematologic neoplasm 5CNS 4Other solid neoplasm 2Other 1NET 1Endocrine 1

Conditions

Advanced Solid Tumor 30Mesothelioma 20Solid Tumor 18Mesothelioma, Malignant 18Advanced Solid Tumors 18Solid Tumors 16Solid Tumor, Adult 11Melanoma 10Carcinoma, Non-Small-Cell Lung 10Ovarian Neoplasms 8Colorectal Neoplasms 8Retinoblastoma 7Carcinoma, Renal Cell 7Uterine Cervical Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Lung Neoplasms 6Cholangiocarcinoma 6Advanced Malignant Solid Neoplasm 6Triple Negative Breast Neoplasms 5Sarcoma 5Stomach Neoplasms 4Pancreatic Neoplasms 4Malignant Solid Neoplasm 4Esophageal Neoplasms 4Advanced or Metastatic Solid Tumors 4Small Cell Lung Carcinoma 3Neoplasms 3Malignant Solid Tumor 3Locally Advanced or Metastatic Solid Tumors 3Hematopoietic and Lymphatic System Neoplasm 3

Interventions

pembrolizumab 1obinutuzumab 1naptumomab estafenatox 1durvalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × Other solid neoplasm × Clear all
NCT03983954 2025-11-28

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.

NeoTX Therapeutics Ltd.

Phase 1 Active not recruiting
120 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Prostatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT05215574 2024-10-10

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Active not recruiting
130 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡